For research use only. Not for therapeutic Use.
TRAM-39 is a selective blocker of intermediate conductance Ca2+-activated K+ (IKCa) channels. TRAM-39 inhibits KCa3.1 channel with an IC50 value of 60 nM. TRAM-39 can be used for the research of ataxia, epilepsy, memory disorders, schizophrenia and Parkinson’s disease[1][2][3][4].
TRAM-39 (1 μM) reduces the peak amplitude of gKCa2 in sympathetic LAH neurons (mean percentage change 56%) in BAE cells[2].
TRAM-39 (200 nM) diminishes lipopolysaccharide (LPS)-induced cryptdin release from paneth cells[3].
TRAM-39 (1 μM; adds to the perfusate) fully blocks all IKCa channels in multicellular preparations[1].
| Catalog Number | I011059 |
| CAS Number | 197525-99-8 |
| Synonyms | 2-(2-chlorophenyl)-2,2-diphenylacetonitrile |
| Molecular Formula | C20H14ClN |
| Purity | ≥95% |
| InChI | InChI=1S/C20H14ClN/c21-19-14-8-7-13-18(19)20(15-22,16-9-3-1-4-10-16)17-11-5-2-6-12-17/h1-14H |
| InChIKey | JHNRTPKGSCVKKC-UHFFFAOYSA-N |
| SMILES | C1=CC=C(C=C1)C(C#N)(C2=CC=CC=C2)C3=CC=CC=C3Cl |
| Reference | [1]. Davies PJ, et al. Different types of potassium channels underlie the long afterhyperpolarization in guinea-pig sympathetic and enteric neurons. Auton Neurosci. 2006 Jan 30;124(1-2):26-30. [2]. Burnham MP, et al. Impaired small-conductance Ca2+-activated K+ channel-dependent EDHF responses in Type II diabetic ZDF rats. Br J Pharmacol. 2006 Jun;148(4):434-41. [3]. Ayabe T, et al. Modulation of mouse Paneth cell alpha-defensin secretion by mIKCa1, a Ca2+-activated, intermediate conductance potassium channel. J Biol Chem. 2002 Feb 1;277(5):3793-800. [4]. Wulff H, et al. Modulators of small- and intermediate-conductance calcium-activated potassium channels and their therapeutic indications. Curr Med Chem. 2007;14(13):1437-57. |
